30-Second Takeaway
- Nonrandomized RP vs RT comparisons show author specialty influences conclusions; multidisciplinary review advised.
- Patient-reported outcome deterioration often precedes imaging-detected breast cancer relapse and improves survival prediction when combined with PFS.
Latest - Week ending July 4, 2026
Grand Rounds: Selected recent oncology evidence briefs
Author specialty associates with direction of nonrandomized RP vs RT conclusions
In 105 nonrandomized studies comparing radical prostatectomy (RP) and radiation therapy (RT), 44% reported no conclusive difference, 42% favored RP, and 14% favored RT. Multivariate analysis showed use of national databases (p=0.01) and urology author specialty (p=0.01) predicted conclusions aligned with the authors' specialty. The association persisted after excluding studies relying only on biochemical recurrence (p=0.006). Implication: interpret nonrandomized RP vs RT findings with multidisciplinary input and scrutiny of data sources.
PRO deterioration precedes imaging relapse and boosts OS prediction when combined with PFS
Across 2,738 breast cancer patients with 445,239 PRO entries, 89.2% experienced PRO deterioration before radiographic relapse. PRO worsening occurred a median of 85 versus 706 days before relapse detection and correlated with metastatic site, tumor size, and survival. Machine learning combining PRO deterioration times and PFS achieved AUC 0.932 for OS prediction versus 0.806 for PROs alone. Implication: consider implementing regular PRO capture as an adjunct surveillance signal, while validating thresholds and false-positive rates locally.
PRO-PLATINUM RCT tests a 5‑strain probiotic during platinum chemotherapy for ovarian cancer
PRO-PLATINUM is a double-blind, placebo-controlled trial randomizing 124 stage II–IV or platinum-sensitive recurrent ovarian cancer patients 1:1 to a 5‑strain probiotic versus placebo during six cycles of platinum chemotherapy. Primary endpoint is change in gut microbiome composition by whole-genome metagenomics; secondary endpoints include feasibility, safety, and survival outcomes. Intervention includes inulin and strains such as Akkermansia muciniphila and Bifidobacterium infantis, with serial stool, blood, and vaginal sampling planned. Implication: probiotic modulation is experimental; await safety, microbiome, and clinical outcome results before clinical adoption.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.